GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Palatin Technologies PTN · USD

Health Care · US listing · 🇺🇸 United States

Compare

7.23

+15.31%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Palatin Technologies

From its filings with the US Securities and Exchange Commission

SEC filings

Palatin Technologies is based in Cranbury, New Jersey and is incorporated in New Jersey. Its shares trade on Nasdaq under the ticker PTN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $8.8m and a net loss of $8.4m. At that date it held total assets of $8.5m and shareholders' equity of $6.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
21 Dec 1999
Employees
20
Website
palatin.com ↗
Head office
4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512
Incorporated in
NJ
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. John PrendergastIndependent Chairman of the Board, since 1996$154,806
  • Dr. Carl SpanaPresident, Chief Executive Officer, Director, since 1996$1.4m
  • Mr. Stephen WillsChief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary$1.4m
  • Mr. Robert DeveerIndependent Director$112,872
  • Dr. Alan DuntonIndependent Director$112,872
  • Mr. Joseph HullIndependent Director$102,872
  • Dr. Anthony ManningIndependent Director$97,872
  • Ms. Arlene MorrisIndependent Director$97,872

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
56
Environment
57
Social
80
Governance
30
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Biopharmaceutical focus on melanocortin and natriuretic peptide receptor systems.
  • 20 full-time employees support targeted therapeutic development.
  • Cranbury, New Jersey headquarters provides strategic location.

Weaknesses

  • Limited employee count of 20 hinders rapid development.
  • US headquarters may limit global market access.
  • 1999 listing date indicates long-standing operations.

Opportunities

  • Melanocortin receptor system offers treatments for unmet medical needs.
  • Natriuretic peptide receptor system targets cardiovascular diseases.
  • Receptor-specific therapeutics have commercial potential in Health Care sector.

Threats

  • Biotechnology sector faces intense competition from larger firms.
  • Regulatory challenges may delay product approvals.
  • Health Care industry requires significant R&D investment.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.